{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:02Z","timestamp":1786119482332,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1097\/mjt.0b013e3181a3e50b","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T01:56:03Z","timestamp":1268790963000},"page":"148-158","source":"Crossref","is-referenced-by-count":31,"title":["Risk of Chemotherapy-Induced Peripheral Neuropathy in Large Population-Based Cohorts of Elderly Patients With Breast, Ovarian, and Lung Cancer"],"prefix":"10.1097","volume":"17","author":[{"given":"Zhannat","family":"Nurgalieva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Burau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin L","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-5-20210202","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/01.WNL.0000043691.53710.53","article-title":"Toxic neuropathy in patients with preexisting neuropathy.","volume":"60","author":"Chaudhry","year":"2003","journal-title":"Neurology"},{"key":"R4-5-20210202","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11910-008-0010-5","article-title":"Chemotherapy-induced peripheral neuropathy.","volume":"8","author":"Malik","year":"2008","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R5-5-20210202","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","article-title":"Chemotherapy-induced peripheral neuropathy.","volume":"249","author":"Quasthoff","year":"2002","journal-title":"J Neurol"},{"key":"R6-5-20210202","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents.","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"R7-5-20210202","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","article-title":"Chemotherapy-induced neuropathy.","volume":"13","author":"Windebank","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"R8-5-20210202","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/WCO.0b013e3282f1a06e","article-title":"Neurologic complications of chemotherapy agents.","volume":"20","author":"Kannarkat","year":"2007","journal-title":"Curr Opin Neurol"},{"key":"R9-5-20210202","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pain.2004.01.021","article-title":"Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients.","volume":"109","author":"Dougherty","year":"2004","journal-title":"Pain"},{"key":"R10-5-20210202","first-page":"107","article-title":"Neurotoxicity of taxol.","volume":"15","author":"Rowinsky","year":"1993","journal-title":"J Natl Cancer Inst Monogr"},{"key":"R11-5-20210202","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1200\/JCO.2004.08.048","article-title":"Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.","volume":"22","author":"Winer","year":"2004","journal-title":"J Clin Oncol"},{"key":"R12-5-20210202","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.","volume":"21","author":"Henderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"R13-5-20210202","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","article-title":"Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.","volume":"23","author":"Mamounas","year":"2005","journal-title":"J Clin Oncol"},{"key":"R14-5-20210202","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"R15-5-20210202","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer.","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R16-5-20210202","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R17-5-20210202","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer.","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"R18-5-20210202","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.","volume":"352","author":"Winton","year":"2005","journal-title":"N Engl J Med"},{"key":"R19-5-20210202","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(06)70804-X","article-title":"Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.","volume":"7","author":"Douillard","year":"2006","journal-title":"Lancet Oncol"},{"key":"R25-5-20210202","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/COC.0b013e3181587890","article-title":"Impact of treatment and socioeconomic status on racial disparities in survival among older women with breast cancer.","volume":"31","author":"Du","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"R26-5-20210202","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bjc.1997.68","article-title":"Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.","volume":"75","author":"Hilkens","year":"1997","journal-title":"Br J Cancer"},{"key":"R27-5-20210202","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2005.06.030","article-title":"Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.","volume":"42","author":"Mielke","year":"2006","journal-title":"Eur J Cancer"},{"key":"R28-5-20210202","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1200\/JCO.2003.01.238","article-title":"Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors.","volume":"21","author":"Goetz","year":"2003","journal-title":"J Clin Oncol"},{"key":"R29-5-20210202","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.410350310","article-title":"Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.","volume":"35","author":"Chaudhry","year":"1994","journal-title":"Ann Neurol"},{"key":"R30-5-20210202","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/A:1023952106955","article-title":"Peripheral neuropathy due to therapy with paclitaxel, gemcitabine and cisplatin in patients with advanced ovarian cancer.","volume":"63","author":"Verstappen","year":"2003","journal-title":"J Neuroonocol"},{"key":"R31-5-20210202","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ijgc-00009577-200307000-00005","article-title":"A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC).","volume":"13","author":"Bacon","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"R32-5-20210202","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/annonc\/mdh395","article-title":"Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.","volume":"15","author":"Fountzilas","year":"2004","journal-title":"Ann Oncol"},{"key":"R33-5-20210202","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1212\/WNL.39.3.368","article-title":"Taxol produces a predominantly sensory neuropathy.","volume":"39","author":"Lipton","year":"1989","journal-title":"Neurology"},{"key":"R34-5-20210202","first-page":"1","article-title":"Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).","volume":"8","author":"Hilkens","year":"1997","journal-title":"Ann Onocol"},{"key":"R35-5-20210202","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.1994.12.6.1238","article-title":"Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.","volume":"12","author":"Fossella","year":"1994","journal-title":"J Clin Oncol"},{"key":"R36-5-20210202","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1002\/cncr.11375","article-title":"Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.","volume":"97","author":"Akerley","year":"2003","journal-title":"Cancer"},{"key":"R37-5-20210202","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00001813-200311000-00003","article-title":"Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h.","volume":"14","author":"Mielke","year":"2003","journal-title":"Anticancer Drugs"},{"key":"R38-5-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1006\/gyno.1996.0090","article-title":"The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer.","volume":"61","author":"Gogas","year":"1996","journal-title":"Gynecol Oncol"},{"key":"R39-5-20210202","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.2174\/092986708786848569","article-title":"Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.","volume":"15","author":"Park","year":"2008","journal-title":"Curr Med Chem"},{"key":"R40-5-20210202","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.coc.0000239135.90175.4f","article-title":"Neuroprotection during chemotherapy: a systematic review.","volume":"30","author":"Walker","year":"2007","journal-title":"Am J Clin Oncol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MJT.0b013e3181a3e50b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:20:17Z","timestamp":1786040417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201003000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181a3e50b","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}